The Food and Drug Administration (FDA) will no longer require premarket review of laboratory developed tests (LDTs), including COVID-19 tests, decline to review emergency use authorization (EUA) request for LDTs. Instead, the FDA will prioritize review of EUAs for point-of-care tests, home collection tests, at-home tests, tests that reduce reliance on test supplies, and high-throughput, widely distributed tests.
FDA Will No Longer Review EUA Requests for COVID-19 Laboratory Developed Tests
More Issues
Wade’s Health Law Highlights for November 17, 2026
OIG approved a drug manufacturer’s plan to pay for autoantibody testing that helps determine whether its drug for a rare lung disease may be…
Wade’s Health Law Highlights for November 10, 2026
Texas secured a $45 million settlement with Gilead Sciences over manufacturer patient support programs it treated as illegal inducements under state law. The Texas…
Wade’s Health Law Highlights for November 3, 2026
HHS will not take enforcement action against 503A compounding pharmacies that make six peptides FDA removed from the compounding bulks list in 2023. The…
